In conclusion, the treatment of anaemia in HD patients with the original IV iron formulation requires lower doses of IV iron and ESAs than the generic iron formulation used in this study to achieve greater TSAT and serum ferritin levels and similarly stable Hb levels. The gene discussed is GSTM1; the disease is anemia.